至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Massively parallel de novo protein design for targeted therapeutics.

Nature. 2017; 
Chevalier Aaron,Silva Daniel-Adriano,Rocklin Gabriel J,Hicks Derrick R,Vergara Renan,Murapa Patience,Bernard Steffen M,Zhang Lu,Lam Kwok-Ho,Yao Guorui,Bahl Christopher D,Miyashita Shin-Ichiro,Goreshnik Inna,Fuller James T,Koday Merika T,Jenkins Cody M,Colvin Tom,Carter Lauren,Bohn Alan,Bryan Cassie M,Fernández-Velasco D Alejandro,Stewart Lance,Dong Min,Huang Xuhui,Jin Rongsheng,Wilson Ian A,Fuller Deborah H,Baker D
Products/Services Used Details Operation
Custom Vector Construction coli plasmid expression vectors (GenScript, N-terminal 6 × His tag and thrombin cleavage site). Get A Quote

摘要

De novo protein design holds promise for creating small stable proteins with shapes customized to bind therapeutic targets. We describe a massively parallel approach for designing, manufacturing and screening mini-protein binders, integrating large-scale computational design, oligonucleotide synthesis, yeast display screening and next-generation sequencing. We designed and tested 22,660 mini-proteins of 37-43 residues that target influenza haemagglutinin and botulinum neurotoxin B, along with 6,286 control sequences to probe contributions to folding and binding, and identified 2,618 high-affinity binders. Comparison of the binding and non-binding design sets, which are two orders of magnitud... More

关键词